New combo therapy targets untreatable liver cancer
NCT ID NCT06040099
First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and bevacizumab) after a procedure that delivers tiny radioactive beads to the liver can help people with liver cancer that cannot be surgically removed. The study includes 58 participants and measures how long the cancer stays under control and what side effects occur. The approach aims to shrink tumors and delay progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (Imfinzi) and bevacizumab (Avastin) given intravenously, plus yttrium-90 glass microspheres (TheraSphere) delivered via a procedure called transarterial radioembolization
What this could lead to
If this works, it could provide a new treatment option for people with liver cancer that cannot be removed by surgery, potentially slowing the cancer's growth.
What could go wrong
This is a small, early-phase study with only 58 participants and no comparison group, so results may not apply to everyone. The combination of treatments can cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Aurora, Colorado, 80045, United States
-
Research Site
Gainesville, Florida, 32608, United States
-
Research Site
Orlando, Florida, 32804, United States
-
Research Site
Atlanta, Georgia, 30322, United States
-
Research Site
Atlanta, Georgia, 30342, United States
-
Research Site
Chicago, Illinois, 60611, United States
-
Research Site
Boston, Massachusetts, 02118, United States
-
Research Site
Detroit, Michigan, 48201, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
Trenton, New Jersey, 08690, United States
-
Research Site
Buffalo, New York, 14263, United States
-
Research Site
New York, New York, 10029, United States
-
Research Site
Chapel Hill, North Carolina, 27599, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Portland, Oregon, 97239, United States
-
Research Site
Philadelphia, Pennsylvania, 19107, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Charlottesville, Virginia, 22908, United States
-
Research Site
Seattle, Washington, 98195, United States
-
Research Site
Milwaukee, Wisconsin, 53215, United States
-
Research Site
Milwaukee, Wisconsin, 53226, United States